Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 4
2020 5
2021 10
2022 24
2023 29
2024 27
2025 44
2026 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment.
Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, Goliopoulou A, Kalogeras K, Tsigkou V, Kalpis A, Paschou SA, Theofilis P, Vavuranakis M, Tousoulis D, Siasos G. Lampsas S, et al. Among authors: theofilis p. Molecules. 2023 Jan 18;28(3):969. doi: 10.3390/molecules28030969. Molecules. 2023. PMID: 36770634 Free PMC article. Review.
Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as they are largely determined by variations in the Lp(a) gene (LPA) locus encoding apo(a). Lp(a) is the preferential lipoprotein carrier for oxidized …
Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as they ar …
Risk factors profile of young and older patients with myocardial infarction.
Sagris M, Antonopoulos AS, Theofilis P, Oikonomou E, Siasos G, Tsalamandris S, Antoniades C, Brilakis ES, Kaski JC, Tousoulis D. Sagris M, et al. Among authors: theofilis p. Cardiovasc Res. 2022 Jul 27;118(10):2281-2292. doi: 10.1093/cvr/cvab264. Cardiovasc Res. 2022. PMID: 34358302 Free article. Review.
Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies.
Karakasis P, Theofilis P, Patoulias D, Vlachakis PK, Antoniadis AP, Fragakis N. Karakasis P, et al. Among authors: theofilis p. Int J Mol Sci. 2025 Feb 28;26(5):2196. doi: 10.3390/ijms26052196. Int J Mol Sci. 2025. PMID: 40076813 Free PMC article. Review.
The global rise in diabetes prevalence has significantly contributed to the increasing burden of atherosclerotic cardiovascular disease (ASCVD), a leading cause of morbidity and mortality in this population. Diabetes accelerates atherosclerosis through mechanisms such as h …
The global rise in diabetes prevalence has significantly contributed to the increasing burden of atherosclerotic cardiovascular disea …
Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome.
Katsioupa M, Kourampi I, Oikonomou E, Tsigkou V, Theofilis P, Charalambous G, Marinos G, Gialamas I, Zisimos K, Anastasiou A, Katsianos E, Kalogeras K, Katsarou O, Vavuranakis M, Siasos G, Tousoulis D. Katsioupa M, et al. Among authors: theofilis p. Life (Basel). 2023 Sep 29;13(10):1992. doi: 10.3390/life13101992. Life (Basel). 2023. PMID: 37895374 Free PMC article. Review.
The burden of cardiovascular diseases and the critical role of acute coronary syndrome (ACS) in their progression underscore the need for effective diagnostic and prognostic tools. ...
The burden of cardiovascular diseases and the critical role of acute coronary syndrome (ACS) in their progression underscore the need …
Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets.
Karakasis P, Theofilis P, Vlachakis PK, Korantzopoulos P, Patoulias D, Antoniadis AP, Fragakis N. Karakasis P, et al. Among authors: theofilis p. Int J Mol Sci. 2024 Dec 30;26(1):209. doi: 10.3390/ijms26010209. Int J Mol Sci. 2024. PMID: 39796066 Free PMC article. Review.
Emerging therapeutic strategies include antifibrotic agents targeting the renin-angiotensin-aldosterone system, novel pathways like TGF-beta signaling, and cardio-metabolic drugs like SGLT2 inhibitors and GLP-1 receptor agonists. ...
Emerging therapeutic strategies include antifibrotic agents targeting the renin-angiotensin-aldosterone system, novel pathways like T …
Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk.
Theofilis P, Vlachakis PK, Karakasis P, Kalaitzidis RG. Theofilis P, et al. Curr Atheroscler Rep. 2025 Mar 21;27(1):41. doi: 10.1007/s11883-025-01290-2. Curr Atheroscler Rep. 2025. PMID: 40117057 Review.
RECENT FINDINGS: Recent studies have highlighted the inadequacy of traditional lipid markers like LDL-C in reflecting cardiovascular risk in CKD. Novel biomarkers, such as remnant cholesterol and lipoprotein(a), demonstrate stronger associations with adverse outcomes. ...D …
RECENT FINDINGS: Recent studies have highlighted the inadequacy of traditional lipid markers like LDL-C in reflecting cardiovascular …
Inflammatory Biomarkers in Hypertension.
Tsioufis P, Theofilis P, Dimitriadis K, Vlachakis PK, Iliakis P, Tsiachris D, Tsioufis K, Tousoulis D. Tsioufis P, et al. Among authors: theofilis p. Curr Med Chem. 2025;32(39):8751-8764. doi: 10.2174/0109298673348789250604113545. Curr Med Chem. 2025. PMID: 40671233 Review.
Hypertension remains a leading modifiable risk factor for cardiovascular diseases, yet its underlying mechanisms are not fully understood. Emerging evidence suggests that inflammation plays a central role in the pathogenesis and progression of hypertension. ...These biomar …
Hypertension remains a leading modifiable risk factor for cardiovascular diseases, yet its underlying mechanisms are not fully unders …
Editorial for the Special Issue "Diabetes, Hypertension, and Cardiovascular Diseases: New Insights, Risk Factors, and Drug Therapies".
Theofilis P, Mantzouranis E, Chrysohoou C, Tsioufis K. Theofilis P, et al. Medicina (Kaunas). 2026 Jun 10;62(6):1128. doi: 10.3390/medicina62061128. Medicina (Kaunas). 2026. PMID: 42356140 Free PMC article.
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide [...]....
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide [...]....
Telomere Length: A Cardiovascular Biomarker and a Novel Therapeutic Target.
Sagris M, Theofilis P, Antonopoulos AS, Tsioufis K, Tousoulis D. Sagris M, et al. Among authors: theofilis p. Int J Mol Sci. 2022 Dec 16;23(24):16010. doi: 10.3390/ijms232416010. Int J Mol Sci. 2022. PMID: 36555658 Free PMC article. Review.
In this review, we delve not only into the pathophysiology of TL shortening but also into its association with cardiovascular disease and the progression of atherosclerosis. We also provide current and future treatment options based on TL and telomerase function, trying to …
In this review, we delve not only into the pathophysiology of TL shortening but also into its association with cardiovascular disease …
Inflammatory Mediators of Endothelial Dysfunction.
Dri E, Lampas E, Lazaros G, Lazarou E, Theofilis P, Tsioufis C, Tousoulis D. Dri E, et al. Among authors: theofilis p. Life (Basel). 2023 Jun 20;13(6):1420. doi: 10.3390/life13061420. Life (Basel). 2023. PMID: 37374202 Free PMC article. Review.
Inflammatory modulators/biomarkers, such as IL-1alpha, IL-1beta, IL-6, IL-12, IL-15, IL-18, and tumor necrosis factor alpha, or alternative anti-inflammatory cytokine IL-10, and adhesion molecules (ICAM-1, VCAM-1), involved in atherosclerosis progression have been shown to predic …
Inflammatory modulators/biomarkers, such as IL-1alpha, IL-1beta, IL-6, IL-12, IL-15, IL-18, and tumor necrosis factor alpha, or alternative …
143 results